Search Results

ROCKVILLE, MD and SHENZHEN, CHINA, HighTide Therapeutics, Inc. (Stock Code: 2511.HK), a clinical stage biopharmaceutical company specializing in the development of multi-targeted therapies for chronic liver and metabolic diseases, announced that it will make multiple presentations at the European Association for the Study of the Liver (EASL) Congress, taking place from June 5-8, 2024 in Milan, Italy.

Rational Vaccines and Shenzhen Mellow Hope Pharm Industrial Co., Ltd. announced they have reached an agreement to jointly develop, manufacture, and commercialize live vaccines against herpes simplex viruses.

Novotech, the global full-service clinical Contract Research Organization that partners with biotech companies to accelerate the development of advanced and novel therapeutics at every phase, announced it has signed a Memorandum of Understanding with Hong Kong-Shenzhen Innovation and Technology Park Limited.

Bowen Acquisition Corp, a special purpose acquisition company, announced the execution of an agreement and plan of merger with Shenzhen Qianzhi BioTechnology Co., Ltd, a biotech company engaged in development, manufacturing and sales of ozonated health and wellness products in China.

On June 9, the Summit Forum on the Application and Construction of AGP in China, led by the National Innovation Center for Advanced Medical Devices, sponsored by China AGP and Digital Therapeutics R&D Center, co-sponsored by Shenzhen SiBionics Technology Co., Ltd. took place in Shenzhen, which aimed to promote the application of ambulatory glucose profile in precision diagnosis and treatment and lead the continuous development of digital management for diabetes.

SMITM CAPITAL MARKETS LTD, has announced a significant agreement with Mid-Atlantic BioTherapeutics, Inc. (MABT), a clinical-stage ready US biopharmaceutical company.